An Australian stem cell and regenerative medicine company

May 23, 2019

Shaw and Partners Research Update: “Management and Board Additions Indicate Confidence; ‘Buy’ Rating; Price Target $2.50

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

March 28, 2019

Shaw and Partners Research Update: “Extension of Option Delivers Buying Opportunity; ‘Buy’ Rating; Price Target $2.50”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

March 25, 2019

H.C. Wainwright & Co. Research Update: “FUJIFILM Delay Merely a Bump in the Road, We Believe; Reiterate Buy”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating

December 13, 2018

H.C. Wainwright & Co. Research Update: Research Funding Awarded; Tax Credits Received; Reiterate Buy

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating

September 17, 2018

H.C. Wainwright & Co. Research Update: “Recent Developments Underscore Clinical Progress; FUJIFILM May Exercise Option Soon; Raising Target to A$2”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and raising his price target to $2.00